 |
 |
vbn6 wrote: > > on Sun, 7 Nov 1999 07:15:15 -0800 > J. R. Bruman wrote: > > >> By the way, a substitute MAO inhibitor, that doesn't metabolize to > amphetamine, is under development<< > > Where, who and when, Joe? (from Current Science Reviews, May 99): Advt; J Neur N'surg Psych 1999;66:2nd cover: For those who don't like the stimulation of selegiline (Eldepryl) in its current form, a new formulation is available in which a single 1.25mg dose daily is equivalent to the usual 5mg twice a day, and whose amphetamine metabolite is reduced 90%. It's sold in the UK by Athena Neurosciences under the name Zelapar; I don't know yet about U.S. approval. Cheers, Joe -- J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks, CA 91403-5013